| Literature DB >> 25379337 |
David P Overy1, Fabrice Berrue2, Hebelin Correa3, Novriyandi Hanif4, Kathryn Hay5, Martin Lanteigne4, Kathrine Mquilian3, Stephanie Duffy3, Patricia Boland4, Ramesh Jagannathan3, Gavin S Carr3, Marieke Vansteeland3, Russell G Kerr6.
Abstract
Due to a rate increase in the resistance of microbial pathogens to currently used antibiotics, there is a need in society for the discovery of novel antimicrobials. Historically, fungi are a proven source for antimicrobial compounds. The main goals of this study were to investigate the fungal diversity associated with sea foam collected around the coast of Prince Edward Island and the utility of this resource for the production of antimicrobial natural products. Obtained isolates were identified using ITS and nLSU rDNA sequences, fermented on four media, extracted and fractions enriched in secondary metabolites were screened for antimicrobial activity. The majority of the isolates obtained were ascomycetes, consisting of four recognized marine taxa along with other ubiquitous genera and many 'unknown' isolates that could not be identified to the species level using rDNA gene sequences. Secondary metabolite isolation efforts lead to the purification of the metabolites epolones A and B, pycnidione and coniothyrione from a strain of Neosetophoma samarorum; brefeldin A, leptosin J and the metabolite TMC-264 from an unknown fungus (probably representative of an Edenia sp.); and 1-hydroxy-6-methyl-8-hydroxymethylxanthone, chrysophanol and chrysophanol bianthrone from a Phaeospheria spartinae isolate. The biological activity of each of these metabolites was assessed against a panel of microbial pathogens as well as several cell lines.Entities:
Keywords: Neosetophoma samarorum; Phaeosphaeria spartinae; antimicrobials; fungal diversity; sea foam; secondary metabolites
Year: 2014 PMID: 25379337 PMCID: PMC4205912 DOI: 10.1080/21501203.2014.931893
Source DB: PubMed Journal: Mycology ISSN: 2150-1203
Figure 1. Bootstrap consensus tree inferred from 2000 replicates generated using the neighbor-joining method. Evolutionary distances were computed using the Maximum Composite Likelihood method. Numbers denote the percentage of replicate trees in which the associated taxa clustered together in the bootstrap test; only confidence values above 50% are indicated. RKDO isolates in bold font represent isolates that were screened for antimicrobial activity. Observed antimicrobial activities tested at 250 μg/mL are presented in brackets behind the isolate number (green = > 60% inhibition, red = > 80% inhibition, MRSA = methicillin-resistant Staphylococcus aureus, S.war = S. warneri, VRE = vancomycin-resistant Enterococcus faecium, P. aer = Pseudomonas aeruginosa, P. vul = Proteus vulgaris, and C.alb = Candida albicans). Species names in blue font represent true marine lineages.
Figure 2. Metabolites isolated from Neosetophoma samarorum strain RKDO834.
Figure 3. Phenotypic observations of strain RKDO795 (probable Edenia sp.) (a) colony morphology on CYA media (4 wks growth in 9 cm Petri dish) (b) colony morphology on YES media (4 wks growth in 9 cm Petri dish); (c) hyphal aggregate formed on PDA (scale bar = 2 mm); (d) darkened mycelial strands formed at the point of incoculation on YES (scale bar = 2 mm).
Figure 4. Metabolites isolated from strain RKDO795 (probable Edenia sp.).
Figure 5. Phenotypic observations of strain RKDO785 (Phaeosphaeria spartinae) (a) colony morphology on PDA media, with and without sea salts (2 wks growth on a 9 cm Petri dish); (b) aerial mycelia demonstrating pigmentation (scale bar = 250 μm); (c) mycelia viewed in bright field microscopy at 100× magnification (scale bar = 20 μm); pigmentation is evident within mycelia (arrows indicate exudate crystals).
Figure 6. Metabolites isolated from Phaeosphaeria spartinae strain RKDO795.
Comparison of metabolites identified from P. spartinae strains RKDO785 and RKDO808 cultured in rice medium.
| Compound | LCMS Rt (min) | [M + H]+, [M + Na]+, or [M–H]– | Metabolite class | RKDO 785 | RKDO 808 |
|---|---|---|---|---|---|
| 3.72 | +257.0809 [M + H]+ | Xanthone | + | + | |
| 4.29 | −253.0498 [M–H]– | Chrysophanol | + | + | |
| 4.28 | −293.2116 [M–H]– | Fatty acid | – | + | |
| 4.28 | +335.2192 [M + Na]+ | Fatty acid | – | + | |
| 4.52 | −295.2271 [M–H]– | Fatty acid | – | + | |
| 4.51 | +337.2349 [M + Na]+ | Fatty acid | – | + | |
| 4.9 | −507.1072 [M–H]– | Bianthrone | + | + | |
| 5.15 | −523.1025 [M–H]– | Bianthrone | + | + | |
| 5.16 | −477.1331 [M–H]– | Bianthrone | + | + |
Biological activity of isolated metabolites against several bacterial pathogens along with antibiotics tested as a positive control. All assays were run in triplicate and averaged (expressed as µg/mL). If assay was not performed, table entry was left blank.
| MRSA | VRE | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| MIC | IC50 | MIC | IC50 | MIC | IC50 | MIC | IC50 | MIC | IC50 | |
| Pycnidione | 16 | 12 | 64 | 12 | 64 | 46 | 64 | 30 | >128 | >128 |
| Epolone A | 64 | 48 | 64 | 33 | >64 | 44 | >64 | >64 | >128 | >128 |
| Epolone B | 64 | 48 | >64 | 52 | >64 | >64 | >128 | >128 | ||
| Coniothyrione | 16 | 8 | 16 | 12 | 16 | 4 | >64 | 30 | >64 | >64 |
| Leptosin J | 2 | 0.7 | 64 | 9 | >128 | 128 | >128 | >128 | >128 | >128 |
| Brefeldin A | >128 | >128 | >128 | >128 | >128 | >128 | >128 | >128 | >128 | >128 |
| TMC-264 | 64 | 14 | 64 | 23 | >128 | 100 | >128 | >128 | >128 | >128 |
| 1-Hydroxy-6-methyl-8-hydroxymethylxanthone | >128 | >128 | >128 | >128 | >128 | >128 | >128 | >128 | >128 | >128 |
| Chrysophanol | >128 | >128 | >128 | >128 | >128 | >128 | >128 | >128 | >128 | >128 |
| Chrysophanol bianthrone | >128 | >128 | >128 | >128 | >128 | 128 | >128 | >128 | >128 | >128 |
| Vancomycin | 1.6 | 0.88 | 1 | 0.75 | ||||||
| Rifampicin | 2 | 0.5 | ||||||||
| Ciprofloxacin | 0.25 | 0.063 | ||||||||
| Gentamicin | 2 | 1.25 | ||||||||
Biological activity of isolated metabolites along with positive controls (nystatin, zinc pyrithione, and doxorubicin) tested against the yeast Candida albicans and the cell lines HeKa (keratinocyte), BJ (fibroblast), and HTB-26 (breast cancer). All assays were run in triplicate and averaged (expressed as µg/mL). If assay was not performed, table entry was left blank.
| Keratinocyte | Fibroblast | HTB-26 | ||||||
|---|---|---|---|---|---|---|---|---|
| MIC | IC50 | MIC | IC50 | MIC | IC50 | MIC | IC50 | |
| Pycnidione | 8 | 5 | 64 | 15 | 64 | 11 | ||
| Epolone A | >64 | >64 | 32 | 13 | 32 | 14 | ||
| Epolone B | 64 | 43 | >128 | 50 | >128 | >128 | ||
| Coniothyrione | >64 | >64 | 64 | 5 | ||||
| Leptosin J | >128 | >128 | 0.5 | >0.5 | 16 | 0.5 | 0.5 | >0.5 |
| Brefeldin A | 128 | 20 | >64 | 0.5 | >64 | >64 | >0.5 | >0.5 |
| TMC-264 | >128 | >128 | 4 | 1 | 16 | 13 | 8 | 2.8 |
| 1-Hydroxy-6-methyl-8-hydroxymethylxanthone | >128 | >128 | 16 | 12 | 64 | 29 | 32 | 24 |
| Chrysophanol | >128 | >128 | >64 | >64 | >64 | >64 | >64 | >64 |
| Chrysophanol bianthrone | >128 | >128 | >64 | >64 | >64 | >64 | 64 | 4 |
| Nystatin | 1.6 | 0.92 | ||||||
| Zinc pyrithione | 1 | 0.75 | 8 | 3 | ||||
| Doxorubromycin | >16 | 2.5 | ||||||